newsfilter
← Latest News
Business Wire·

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Led by Existing Top Institutional Investors With Participation From a New Strategic Investor Well Positioned To Execute on Tab-cel® U.S. BLA Approval and Advancement of ATA3219 Further Strengthens Balance Sheet